major depressive disorder
Conditions
Interventions
Blonanserin 1-4 mg will be orally administered once daily after dinner for 8 weeks. (initial dose: 1mg, maximum dose: 6mg)
Sponsors
Department of Psychiatry, Fujita Health University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: DSM-4-TR:MDD Patients with treatment-resistant MDD: aripiprazole 3-15mg
Exclusion criteria
Exclusion criteria: Patient with the following disorders (based on DSM-IV-TR criteria): psychotic disorders, pervasive developmental disorders, bipolar disorder, obsessive-compulsive disorder, Axis-2 disorder. Patients with substance abuse or dependence (excluding nicotine and caffeine) meeting DSM-IV-TR criteria Patients taking MAO inhibitors with in14 days (or Patients treated with MAO inhibitors within 14 days) Patients taking pimozide Patients with QT interval prolongation Patients treated with ECT within the previous 6 months Patients having severe physical disease Patients who are pregnant or may become pregnant Patients at significant risk of suicide (having a score >3 on HAM-D item 11) Patients who had made suicide attempt within the past year
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The Hamilton Rating Scale for Depression assessment at the 8 weeks after the start of interventions | — |
Secondary
| Measure | Time frame |
|---|---|
| Udvalg for kliniske undersogelser side effect rating scale, Drug Induced Extra-Pyramidal Symptons Scale | — |
Countries
Japan
Contacts
Public ContactYuki Matsuda
Fujita Health University School of Medicine Department of Psychiatry
Outcome results
None listed